The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for ...

GLP-1s could help curb substance abuse – including alcohol and opioids, new study finds - Increasingly popular GLP-1 drugs ...

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial ...

A new study found GLP-1 drugs were associated with 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 9:50 AM ESTCompany ParticipantsMartin Hogan - Senior Director ...

Introduction Individuals experiencing moderate to severe mental illness have low rates of workforce inclusion, with a consequence of high welfare dependency, affecting both societal costs and health.

Daridorexant is approved and marketed in Japan as QUVIVIQ® under a commercialization agreement between Nxera and Shionogi. QUVIVIQ®, discovered by Idorsia Pharmaceuticals, is marketed by Idorsia in ...

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.